...
首页> 外文期刊>The Open Clinical Cancer Journal >Individualized Survival and Treatment Response Predictions in Breast Cancer Patients: Involvements of Phospho-EGFR and Phospho-Her2/Neu Proteins
【24h】

Individualized Survival and Treatment Response Predictions in Breast Cancer Patients: Involvements of Phospho-EGFR and Phospho-Her2/Neu Proteins

机译:乳腺癌患者的个体生存和治疗反应预测:磷酸化EGFR和磷酸化Her2 / Neu蛋白的参与。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Our robust prediction system for individual breast cancer patients combines three well-known machinelearning classifiers to provide stable and accurate clinical outcome prediction (N=269). The average performance of the selected classifiers is used as the evaluation criterion in breast cancer outcome predictions. A profile (incorporating histology, lymph node status, tumor grade, tumor stage, ER, PR, Her2eu, patient’s age and smoking status) generated over 95% accuracy in individualized disease-free survival and treatment response predictions. Furthermore, our analysis demonstrated that the measurement of phospho-EGFR and phospho-Her2eu is more powerful in breast cancer survival prediction than that of total EGFR and total Her2eu (p < 0.05). The incorporation of hormone receptor status, Her2eu, patient’s age and smoking status into the traditional pathologic markers creates a powerful standard to perform individualized survival and treatment outcome predictions for breast cancer patients
机译:我们针对乳腺癌患者的强大预测系统结合了三个著名的机器学习分类器,可提供稳定而准确的临床结果预测(N = 269)。所选分类器的平均性能用作乳腺癌结果预测中的评估标准。个性化(无病生存和治疗反应)预测(合并组织学,淋巴结状态,肿瘤等级,肿瘤分期,ER,PR,Her2 / neu,患者年龄和吸烟状态)的概况产生了95%以上的准确性。此外,我们的分析表明,在总生存率方面,磷酸化EGFR和磷酸化Her2 / neu的检测比总EGFR和总Her2 / neu的检测更为有效(p <0.05)。将激素受体状态,Her2 / neu,患者的年龄和吸烟状态纳入传统的病理标志物,为乳腺癌患者进行个性化的生存和治疗结果预测创造了强有力的标准

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号